Public Sector Pension Investment Board Trims Holdings in Teva Pharmaceutical Industries Ltd (NYSE:TEVA)

Public Sector Pension Investment Board trimmed its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 5.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 372,689 shares of the company’s stock after selling 21,613 shares during the period. Public Sector Pension Investment Board’s holdings in Teva Pharmaceutical Industries were worth $3,652,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Covenant Multifamily Offices LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $29,000. Parkside Financial Bank & Trust lifted its holdings in shares of Teva Pharmaceutical Industries by 400.0% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,500 shares of the company’s stock worth $25,000 after acquiring an additional 2,000 shares during the period. Coastal Investment Advisors Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 90.4% during the 4th quarter. Coastal Investment Advisors Inc. now owns 4,002 shares of the company’s stock worth $41,000 after acquiring an additional 1,900 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 329.9% during the 4th quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 4,020 shares of the company’s stock worth $39,000 after acquiring an additional 3,085 shares during the period. Finally, Advisory Services Network LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 181.8% during the 4th quarter. Advisory Services Network LLC now owns 4,230 shares of the company’s stock worth $41,000 after acquiring an additional 2,729 shares during the period. Institutional investors own 53.76% of the company’s stock.

TEVA has been the topic of several recent analyst reports. Cantor Fitzgerald increased their price objective on shares of Teva Pharmaceutical Industries from $9.00 to $15.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. Oppenheimer raised their target price on Teva Pharmaceutical Industries from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, February 13th. Argus raised their target price on Teva Pharmaceutical Industries from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. UBS Group raised their target price on Teva Pharmaceutical Industries from $8.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, February 17th. Finally, Cfra raised their target price on Teva Pharmaceutical Industries from $11.00 to $13.00 and gave the company a “hold” rating in a research note on Wednesday, February 12th. Five equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $11.65.

In related news, insider Mark Sabag sold 72,131 shares of Teva Pharmaceutical Industries stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $13.03, for a total value of $939,866.93. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Deborah A. Griffin sold 4,807 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $11.23, for a total value of $53,982.61. Following the completion of the transaction, the chief accounting officer now directly owns 4,807 shares in the company, valued at approximately $53,982.61. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 127,459 shares of company stock worth $1,590,911. 0.49% of the stock is owned by corporate insiders.

Shares of NYSE TEVA traded up $0.06 during midday trading on Thursday, reaching $7.90. 26,972,822 shares of the company traded hands, compared to its average volume of 23,668,750. Teva Pharmaceutical Industries Ltd has a 52 week low of $6.07 and a 52 week high of $16.31. The stock has a 50-day moving average price of $10.78 and a 200 day moving average price of $9.38. The company has a debt-to-equity ratio of 1.63, a current ratio of 0.98 and a quick ratio of 0.66. The company has a market cap of $8.87 billion, a price-to-earnings ratio of -8.59, a PEG ratio of 0.72 and a beta of 1.53.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.01. The business had revenue of $4.47 billion for the quarter, compared to analysts’ expectations of $4.35 billion. Teva Pharmaceutical Industries had a negative net margin of 5.75% and a positive return on equity of 16.57%. The company’s revenue was up 1.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.53 earnings per share. As a group, analysts expect that Teva Pharmaceutical Industries Ltd will post 2.37 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What is the definition of a trade war?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News